GYRE
NASDAQ
$5.88
Gyre Therapeutics Inc (GYRE)
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary platform that harmoniously combines gene therapy with precision medicine, Gyre is focused on delivering innovative solutions to address significant unmet medical needs. With a robust pipeline and a strong commitment to scientific excellence, the company is well-positioned for sustained growth and impact in the biopharmaceutical sector. Its strategic collaborations and ongoing research and development efforts underscore Gyre's potential to revolutionize treatment paradigms and improve patient outcomes in challenging health conditions.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $18.67 (+217.52%)
Market Cap
$599M
Revenue 5Y CAGR
+80.86%
Free Cash Flow Yield
0.51%
Beta (5Y)
1.45
Price Chart
Valuation
Market Cap$599M
Forward P/E78.12
P/S6.04
P/B6.98
Profitability
Total Revenue (TTM)$117M
Gross Profit (TTM)$111M
EBITDA$2.48M
Profit Margin-43.8%
Operating Margin-41.5%
EPS-$0.04
Financial Health
Free Cash Flow Yield0.51%
Growth & Risk
EPS 5Y CAGR-58.01%
Revenue 5Y CAGR+80.86%
Beta (5Y)1.45
Sharpe Ratio-0.15